#clinical trials

1 article

A wide, softly lit editorial still life on a pale warm-gray stone surface, shot from a slightly elevated three-quarter angle. On the left, a small cluster of fresh yellow-gold onions with papery skins, one cut in half to show its pale concentric layers, sits beside a few dusty-red capers and a sprig of dill. These are natural quercetin sources and read as quiet botanical details. In the center, a minimalist glass apothecary dish holds a few small, round, off-white tablets. Beside it, a slim amber glass vial lies on its side with a plain unlabeled cap.

On the right, a neatly arranged clinical element: a vintage-style wooden-handled stopwatch and a crisp paper stride-length measuring tape curled in a loose spiral, hinting at the 6-minute walk test and gait speed measures. Behind these, a softly out-of-focus wall of pale sage green with a subtle shadow of a window frame cast diagonally across it. A single translucent anatomical line drawing of lungs, rendered in fine charcoal ink on cream paper, leans against the wall, its delicate branching bronchi echoing the veining of a nearby green leaf.

Lighting is soft morning daylight from the upper left, creating gentle long shadows and a calm, thoughtful mood. The palette is muted and modern: butter yellow, sage, cream, warm gray, with small accents of terracotta and amber. Shallow depth of field keeps the tablets and onion sharp while the background melts into a creamy blur. Generous negative space across the upper right makes room for headline overlay. The composition feels like a contemporary science journal or wellness-research magazine cover: clean, tactile, restrained, with subtle film grain and natural color grading. No text, no logos, no people, no futuristic elements.

Los Primeros Humanos en Tomar Dasatinib + Quercetina: Lo que un estudio piloto de 14 pacientes con FPI mostró (y no mostró)

BY DR. SYNAPSE · 15 oct 2026

En 2019, investigadores reportaron el primer uso humano de la combinación senolítica de dasatinib y quercetina en 14 pacientes con fibrosis pulmonar idiopática (FPI). Tras tres semanas de dosificación intermitente, se observaron mejoras en la distancia de la prueba de caminata de 6 min, la velocidad de la marcha y el tiempo para incorporarse de una silla, aunque la función pulmonar no cambió. El estudio, abierto y sin grupo control, también registró un evento adverso serio y síntomas respiratorios, dérmicos y gastrointestinales frecuentes.